Filter your results
- 2
- 1
- 3
- 3
- 2
- 1
- 3
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsAnnals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩
Journal articles
hal-03623367v1
|
||
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsAnnals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩
Journal articles
hal-03376715v1
|
||
|
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agentsBlood Cancer Journal, 2017, 7 (5), pp.e562. ⟨10.1038/bcj.2017.41⟩
Journal articles
hal-01655936v1
|